Pub Date : 2023-09-22DOI: 10.19080/ctoij.2023.25.556156
Sagar kumar Patel
{"title":"An Efficient Breast Cancer Detection Using Jelly Electrophorus Optimization Based Deep 3D Convolution Neural Networks (CNN)","authors":"Sagar kumar Patel","doi":"10.19080/ctoij.2023.25.556156","DOIUrl":"https://doi.org/10.19080/ctoij.2023.25.556156","url":null,"abstract":"","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136098632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-27DOI: 10.19080/ctoij.2021.19.556012
A. Strombom
Worldwide, stomach or gastric cancer is the third leading cause of cancer death. Unfortunately, diagnosis often occurs at a late stage, and standard treatment involving radical surgery results in more than half of patients relapsing locally or with distant metastases. Median survival rarely exceeds 12 months, and in metastatic setting, 5-year survival is less than 10%. Given that standard treatment is not very efficacious, the emphasis needs to be on prevention. Dietary factors have an important impact on gastric carcinogenesis, especially in case of the intestinal type of gastric adenocarcinoma. Healthy dietary habits, that is, high intake of fresh fruits and vegetables, a Mediterranean diet, a low-sodium diet, avoiding salt-preserved food, red and high cured meat, sensible alcohol drinking,
{"title":"Stomach Cancer – Prevention with a Plant-Based Diet","authors":"A. Strombom","doi":"10.19080/ctoij.2021.19.556012","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556012","url":null,"abstract":"Worldwide, stomach or gastric cancer is the third leading cause of cancer death. Unfortunately, diagnosis often occurs at a late stage, and standard treatment involving radical surgery results in more than half of patients relapsing locally or with distant metastases. Median survival rarely exceeds 12 months, and in metastatic setting, 5-year survival is less than 10%. Given that standard treatment is not very efficacious, the emphasis needs to be on prevention. Dietary factors have an important impact on gastric carcinogenesis, especially in case of the intestinal type of gastric adenocarcinoma. Healthy dietary habits, that is, high intake of fresh fruits and vegetables, a Mediterranean diet, a low-sodium diet, avoiding salt-preserved food, red and high cured meat, sensible alcohol drinking,","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87993794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-23DOI: 10.19080/ctoij.2021.19.556011
P. Kalra
{"title":"Rare Case of Synchronous Malignancy in Oral Cavity and Esophagus- Case Report","authors":"P. Kalra","doi":"10.19080/ctoij.2021.19.556011","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556011","url":null,"abstract":"","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79334443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-19DOI: 10.19080/ctoij.2021.19.556010
S. Solmaz
Purpose: This study aims to evaluate the prognostic significance of the aspartate aminotransferase (AST) / alanine aminotransferase (ALT) (De Ritis) ratio in diffuse large b-cell lymphoma ( DLBCL). Material and Method: This retrospective study analyzed newly diagnosed DLBCL patients between December 2003- November 2016 in our hospital. We used the university archive to analyze patient information. De Ritis ratio were calculated using data from the blood samples at the time of diagnosis. We analyzed the effect of the De Ritis ratio on the overall survival (OS) of 225 patients with DLBCL. Results: The mean age of the patients was 60.3(18–95) years, and 57.7 % of them were males. We performed ROC curve analysis to calculate optimal cut off points for the De Ritis ratio at the time of diagnosed. The median De Ritis ratio was 1.30( range 0,26 - 5,84 ). Based on the cutoff points for the De Ritis ratio, patients were separated in two groups: high De Ritis ratio group ( ≥1.30, n: 101 ) and low De Ritis ratio group ( <1.30, n:154 ) ( with sensitivity of 59%, specifity of 40%). We found a significant relationship between OS and De Ritis ratio. In Kaplan Meier analyses, the group with a higher De Ritis ratio had a more unfavorable prognosis for OS ( p=0.027). Conclusion: The De Ritis ratio may provide a cost- effective and sustainable marker for DLBCL patients. A higher De Ritis ratio can be considered as an independent prognostic factor in DLBCL patients.
{"title":"AST/ALT (De ritis) Ratio As a Prognostic Factor in Diffuse Large B-Cell Lymphoma","authors":"S. Solmaz","doi":"10.19080/ctoij.2021.19.556010","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556010","url":null,"abstract":"Purpose: This study aims to evaluate the prognostic significance of the aspartate aminotransferase (AST) / alanine aminotransferase (ALT) (De Ritis) ratio in diffuse large b-cell lymphoma ( DLBCL). Material and Method: This retrospective study analyzed newly diagnosed DLBCL patients between December 2003- November 2016 in our hospital. We used the university archive to analyze patient information. De Ritis ratio were calculated using data from the blood samples at the time of diagnosis. We analyzed the effect of the De Ritis ratio on the overall survival (OS) of 225 patients with DLBCL. Results: The mean age of the patients was 60.3(18–95) years, and 57.7 % of them were males. We performed ROC curve analysis to calculate optimal cut off points for the De Ritis ratio at the time of diagnosed. The median De Ritis ratio was 1.30( range 0,26 - 5,84 ). Based on the cutoff points for the De Ritis ratio, patients were separated in two groups: high De Ritis ratio group ( ≥1.30, n: 101 ) and low De Ritis ratio group ( <1.30, n:154 ) ( with sensitivity of 59%, specifity of 40%). We found a significant relationship between OS and De Ritis ratio. In Kaplan Meier analyses, the group with a higher De Ritis ratio had a more unfavorable prognosis for OS ( p=0.027). Conclusion: The De Ritis ratio may provide a cost- effective and sustainable marker for DLBCL patients. A higher De Ritis ratio can be considered as an independent prognostic factor in DLBCL patients.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90797795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-09DOI: 10.19080/ctoij.2021.19.556008
Swati Virmani
Skeletal muscle metastases from hypo pharynx cancer are a very rare finding. The most common metastases in hypo pharynx cancer are seen to lungs, bones and liver. However, here we present a rare case of carcinoma hypopharynx with skeletal metastases to rectus abdominis muscle. Patient was a documented case of multiple metastases to bone, adrenals and skeletal muscle as per whole body PET-CT scan. Skeletal muscle metastases are rare and has no specific pattern of occurrence. Skeletal muscle metastases should always be considered as differential diagnosis for soft tissue sarcoma therefore, such patients should be looked with suspicion and needle biopsy is mandatory for final diagnosis.
{"title":"Skeletal Muscle Metastases in Carcinoma Hypo Pharynx – a Rare Occurrence","authors":"Swati Virmani","doi":"10.19080/ctoij.2021.19.556008","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556008","url":null,"abstract":"Skeletal muscle metastases from hypo pharynx cancer are a very rare finding. The most common metastases in hypo pharynx cancer are seen to lungs, bones and liver. However, here we present a rare case of carcinoma hypopharynx with skeletal metastases to rectus abdominis muscle. Patient was a documented case of multiple metastases to bone, adrenals and skeletal muscle as per whole body PET-CT scan. Skeletal muscle metastases are rare and has no specific pattern of occurrence. Skeletal muscle metastases should always be considered as differential diagnosis for soft tissue sarcoma therefore, such patients should be looked with suspicion and needle biopsy is mandatory for final diagnosis.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84472741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-24DOI: 10.19080/ctoij.2021.19.556007
Anu Bajaj
Meningioma is a commonly discerned, benign neoplasm of the central nervous system originating from cellular elements of meninges, particularly the arachnoid villous structures and meningothelial cells. The neoplasm is uncommonly delineated within extracranial or ectopic sites. Thus, ectopic meningioma infrequently emerges within extracranial or extra-osseous region of the head and neck or maxilla and mandible and may manifest as a cystoid lesion [1]. Meningioma is appropriately established with ultrastructural examination and cogent immunohistochemistry. The morphology and immunohistochemistry of ectopic meningioma is identical to the frequently discerned intracranial meningioma. Appropriate discernment of an extracranial meningioma is challenging, and misinterpretation may incur an inadequate clinical and surgical management, especially for tumours situated within the facial region.
{"title":"The Luxated Eddies-Ectopic Meningioma","authors":"Anu Bajaj","doi":"10.19080/ctoij.2021.19.556007","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556007","url":null,"abstract":"Meningioma is a commonly discerned, benign neoplasm of the central nervous system originating from cellular elements of meninges, particularly the arachnoid villous structures and meningothelial cells. The neoplasm is uncommonly delineated within extracranial or ectopic sites. Thus, ectopic meningioma infrequently emerges within extracranial or extra-osseous region of the head and neck or maxilla and mandible and may manifest as a cystoid lesion [1]. Meningioma is appropriately established with ultrastructural examination and cogent immunohistochemistry. The morphology and immunohistochemistry of ectopic meningioma is identical to the frequently discerned intracranial meningioma. Appropriate discernment of an extracranial meningioma is challenging, and misinterpretation may incur an inadequate clinical and surgical management, especially for tumours situated within the facial region.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85493921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-22DOI: 10.19080/ctoij.2021.19.556005
Dilbag Singh
Clavicular swellings constitute an important underdiagnosed entity in clinics. The reason for this includes mild nature of symptoms and thus less emphasis given to them by the patient as well as treating physician. It is important to do thorough examination and early investigations as this may point towards the diagnosis of a specific inflammatory, infectious, or neoplastic disorder. Moreover, in countries with a very high burden of tuberculosis (TB) like India, it becomes pivotal to first rule out extrapulmonary lymph node TB. Also, the failure to recognize and treat the specific condition can significantly add up to the morbidity and the resultant mortality. Clavicular swelling or fractures can occasionally be a presentation of solitary plasmacytomas but, multiple myeloma involving clavicle is extremely rare. 10-40% cases of multiple myeloma are asymptomatic and incidentally detected. We present a case of 57 years old female with a left clavicular swelling, which was examined and diagnosed as multiple myeloma.
{"title":"Multiple Myeloma Presenting as a Left Clavicular Swelling – A Case Report","authors":"Dilbag Singh","doi":"10.19080/ctoij.2021.19.556005","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556005","url":null,"abstract":"Clavicular swellings constitute an important underdiagnosed entity in clinics. The reason for this includes mild nature of symptoms and thus less emphasis given to them by the patient as well as treating physician. It is important to do thorough examination and early investigations as this may point towards the diagnosis of a specific inflammatory, infectious, or neoplastic disorder. Moreover, in countries with a very high burden of tuberculosis (TB) like India, it becomes pivotal to first rule out extrapulmonary lymph node TB. Also, the failure to recognize and treat the specific condition can significantly add up to the morbidity and the resultant mortality. Clavicular swelling or fractures can occasionally be a presentation of solitary plasmacytomas but, multiple myeloma involving clavicle is extremely rare. 10-40% cases of multiple myeloma are asymptomatic and incidentally detected. We present a case of 57 years old female with a left clavicular swelling, which was examined and diagnosed as multiple myeloma.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82069834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-22DOI: 10.19080/ctoij.2021.19.556006
Amani Saleh Hadi Saeed
Peripheral neuropathy induced by chemotherapy is considered the most common neurological disorder associated with chemotherapy. Different sites are involved in the mechanism of chemotherapy induced peripheral neuropathy and considered multifactorial. 68% of cases develop CIPN during the first month following the start of chemotherapy, 60% of cases develop CIPN within 3 months after chemotherapy and only 30% after 6 months. CIPN is caused by chemotherapeutic agents which include taxanes, platinum analogs, and vinca alkaloids. The clinical presentation of CIPN includes multiple symptoms that may cause functioning impairment and may require reduction of the dose of chemotherapy. CIPN considered a common sequel of different agents of chemotherapy and may last from months to years after chemotherapy completion. CIPN can be diagnosed by a detailed history and clinical examination. Clinical examination of a patient with CIPN can be done by the use of nerve conduction studies. Antidepressant includes tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors are common drugs used for CIPN. Patients may require reductions, substitutions, or stopping of chemotherapeutic agents according to the severity of symptoms.
{"title":"Chemotherapy Induced Peripheral Neuropathy in Breast Cancer Patients","authors":"Amani Saleh Hadi Saeed","doi":"10.19080/ctoij.2021.19.556006","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556006","url":null,"abstract":"Peripheral neuropathy induced by chemotherapy is considered the most common neurological disorder associated with chemotherapy. Different sites are involved in the mechanism of chemotherapy induced peripheral neuropathy and considered multifactorial. 68% of cases develop CIPN during the first month following the start of chemotherapy, 60% of cases develop CIPN within 3 months after chemotherapy and only 30% after 6 months. CIPN is caused by chemotherapeutic agents which include taxanes, platinum analogs, and vinca alkaloids. The clinical presentation of CIPN includes multiple symptoms that may cause functioning impairment and may require reduction of the dose of chemotherapy. CIPN considered a common sequel of different agents of chemotherapy and may last from months to years after chemotherapy completion. CIPN can be diagnosed by a detailed history and clinical examination. Clinical examination of a patient with CIPN can be done by the use of nerve conduction studies. Antidepressant includes tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors are common drugs used for CIPN. Patients may require reductions, substitutions, or stopping of chemotherapeutic agents according to the severity of symptoms.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91356965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-21DOI: 10.19080/ctoij.2019.18.556003
G. Lohith
To compare the metabolic tumor response and volumetric tumor response to pathological tumor response to NACT and to predict the sensitivity, specificity, positive predictive value and negative predictive value of FDG PET to neoadjuvant chemotherapy. Material and method: The study was performed after institutional ethical committee clearance.35 consecutive eligible patients treated between January 2015 to May 2016 were included in the study. PETCT was acquired at baseline and post neoadjuvant chemotherapy, prior to surgery. The SUV max of tumor and involved nodes at baseline and post neoadjuvant chemotherapy was compared to pathological tumor size and nodal status. Response was assessed using PRECIST and RECIST criteria. Statistical methods used for analysis were software SPSS version 13, calculations for Sensitivity, specificity, positive predictive value and negative predictive value. Results: The median age was 51.3 years (range 33 to 68 years). The patients were generally healthy with ECOG PS 0-1. FDG PET tumor to HPE correlation -sensitivity, specificity, PPV, NPV SENSITIVITY 88.8% SPECIFICITY 50% PPV 85.7% NPV 57.1% our results show the high sensitivity and low specificity of PETCT in detecting residual tumor. Overall PCR was in 22.6% (8/35). Pathological Complete Response Rates In The Axillary Node Luminal wise:Total:23/35 – 65.7%. Luminal A PCR Rate -14.4%; Luminal B PCR Rate-8.5%; TNBC PCR Rate-31.4%; HER 2-11.4%. Conclusion:
比较NACT对代谢性肿瘤反应和体积性肿瘤反应对病理性肿瘤反应的影响，预测FDG PET对新辅助化疗的敏感性、特异性、阳性预测值和阴性预测值。材料和方法:本研究经机构伦理委员会批准后进行。研究纳入了2015年1月至2016年5月期间连续治疗的35例符合条件的患者。在手术前的基线和新辅助化疗后进行PETCT检查。将基线和新辅助化疗后肿瘤和受病灶淋巴结的SUV max与病理肿瘤大小和淋巴结状态进行比较。使用PRECIST和RECIST标准评估反应。统计方法采用SPSS version 13软件，计算敏感性、特异性、阳性预测值和阴性预测值。结果:中位年龄为51.3岁(33 ~ 68岁)。患者总体健康，ECOG PS 0-1。FDG PET肿瘤与HPE的相关性-敏感性、特异性、PPV、NPV敏感性88.8%特异性50% PPV 85.7% NPV 57.1%我们的结果显示PETCT检测残余肿瘤的敏感性高，特异性低。总体PCR阳性率为22.6%(8/35)。腋窝淋巴结病理完全缓解率:总:23/35 - 65.7%。Luminal A PCR率-14.4%;Luminal B PCR率-8.5%;TNBC PCR率-31.4%;她的2 - 11.4%。结论:
{"title":"FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumor Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties","authors":"G. Lohith","doi":"10.19080/ctoij.2019.18.556003","DOIUrl":"https://doi.org/10.19080/ctoij.2019.18.556003","url":null,"abstract":"To compare the metabolic tumor response and volumetric tumor response to pathological tumor response to NACT and to predict the sensitivity, specificity, positive predictive value and negative predictive value of FDG PET to neoadjuvant chemotherapy. Material and method: The study was performed after institutional ethical committee clearance.35 consecutive eligible patients treated between January 2015 to May 2016 were included in the study. PETCT was acquired at baseline and post neoadjuvant chemotherapy, prior to surgery. The SUV max of tumor and involved nodes at baseline and post neoadjuvant chemotherapy was compared to pathological tumor size and nodal status. Response was assessed using PRECIST and RECIST criteria. Statistical methods used for analysis were software SPSS version 13, calculations for Sensitivity, specificity, positive predictive value and negative predictive value. Results: The median age was 51.3 years (range 33 to 68 years). The patients were generally healthy with ECOG PS 0-1. FDG PET tumor to HPE correlation -sensitivity, specificity, PPV, NPV SENSITIVITY 88.8% SPECIFICITY 50% PPV 85.7% NPV 57.1% our results show the high sensitivity and low specificity of PETCT in detecting residual tumor. Overall PCR was in 22.6% (8/35). Pathological Complete Response Rates In The Axillary Node Luminal wise:Total:23/35 – 65.7%. Luminal A PCR Rate -14.4%; Luminal B PCR Rate-8.5%; TNBC PCR Rate-31.4%; HER 2-11.4%. Conclusion:","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90047364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-16DOI: 10.19080/ctoij.2021.18.555979
Jose Gabriel Negron Rodriguez, Luis Orrego Poma, Manuel Leiva Gálvez, Maria Claudia Rodriguez Zavaleta, Wuilbert Rodriguez Pantigoso
Non-small cell lung carcinoma (NSCLC) is considered the first cause of cancer-related death worldwide and many therapies have been developed against the presence of actionable mutations. For example, targeting the EGFR mutation has changed the overall prognosis in NSCLC. However, resistance to treatment has emerged and many canonical mechanisms have already been described. NF1 mutation causes partial or total loss of function of neurofibromin, which activates several intracellular pathways (MAPK / ERK, PI3K / AKT, TGF -β / Smad), producing cellular proliferation, migration, apoptosis resistance and genetic instability, leading to loss of EGFR expression. Herein, we describe a case of a novel activation of a non-canonical pathway that led to treatment resistance by NF1 mutation.
{"title":"Loss of EGFR Mutation Expression Induced by NF1 Mutation in Non-Small Cell Lung Cancer: Non-Canonical Pathway of Tyrosine Kinase Inhibitors’ Resistance","authors":"Jose Gabriel Negron Rodriguez, Luis Orrego Poma, Manuel Leiva Gálvez, Maria Claudia Rodriguez Zavaleta, Wuilbert Rodriguez Pantigoso","doi":"10.19080/ctoij.2021.18.555979","DOIUrl":"https://doi.org/10.19080/ctoij.2021.18.555979","url":null,"abstract":"Non-small cell lung carcinoma (NSCLC) is considered the first cause of cancer-related death worldwide and many therapies have been developed against the presence of actionable mutations. For example, targeting the EGFR mutation has changed the overall prognosis in NSCLC. However, resistance to treatment has emerged and many canonical mechanisms have already been described. NF1 mutation causes partial or total loss of function of neurofibromin, which activates several intracellular pathways (MAPK / ERK, PI3K / AKT, TGF -β / Smad), producing cellular proliferation, migration, apoptosis resistance and genetic instability, leading to loss of EGFR expression. Herein, we describe a case of a novel activation of a non-canonical pathway that led to treatment resistance by NF1 mutation.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72707847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：